주 텍스트로 건너뛰기

Investor Relations

Nitto always aims for fair disclosure to ensure that our investors can properly evaluate our corporate value.

Nitto always aims for fair disclosure to ensure that our investors can properly evaluate our corporate value.

What's New RSS

The Nitto website is currently under system maintenance. Please try again later.
2016/Nov/11 Bristol-Myers Squibb, Nitto Denko와 NASH로 인한 진행성 비알코올 지방간염(NASH)과 간경변의 표적 siRNA 치료를 위한 전 세계 배타적 라이선스 계약 체결
2016/Nov/02 계절성 독감 HA 백신 설하정에 대한 제1상 임상시험 개시
2016/Oct/31 Notice Regarding Dividends from Surplus and Revision of Dividend Forecast
Notice
 
Please be advised that except for current and past facts, the performance outlooks and business strategies presented in this Website are based on projections and judgments by NITTO DENKO management, and may differ from the actual performance.

Moreover, as it is not the intention of this Website to solicit any investments in NITTO DENKO stocks, visitors intending to do so are advised to make their investment decisions solely based on their own judgment.

페이지 맨 위로 돌아가기